Superworth

Usana Health Sciences EV/EBIT USNA

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026
2.2×
10-year median
8.2×
Against its 10-year history
0th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.9× to 19.9×
Peer median
15.6×

Usana Health Sciences' EV/EBIT is 2.2× as of Oct 23, 2026.

That is below its ten-year median of 8.2×, lower than on 100% of days in the last ten years.

Over that time it ranged from 1.9× in Aug 2026 to 19.9× in Jul 2018.

The median for 8 chemicals stocks of a similar size is 15.6×.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.2×1.9×6.4×
20255.2×2.4×8.0×
20243.8×3.3×7.3×
20237.9×5.9×10.1×
20226.6×5.4×9.0×
20219.0×7.7×10.5×
20208.0×5.6×11.3×
201910.4×6.4×14.2×
201813.6×11.9×19.9×
201712.3×4.0×12.5×
20164.3×4.2×11.5×
201510.5×10.0×15.8×
201410.6×6.0×12.6×
20138.3×4.7×10.4×
20124.2×4.2×7.6×

Against its peers

Companies in Chemicals nearest Usana Health Sciences' size, closest first, today.

CompanyEV/EBIT
USNAUsana Health Sciences2.2×
NAGENiagen Bioscience14.9×
FTLFFitlife Brandsn/m
FTKFlotek Industries23.7×
CRONCronosn/m
BTMDbiote10.5×
ROGRogers16.3×
NGVTIngevity16.8×
IOSPInnospec12.0×
Peer median15.6×

Where Usana Health Sciences ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Usana Health Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.